Back to Search
Start Over
Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn)
- Source :
- Journal of Antimicrobial Chemotherapy, Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 2019, 74 (11), pp.3315-3327. ⟨10.1093/jac/dkz344⟩, Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 2019, Journal of Antimicrobial Chemotherapy, 74 (11), pp.3315-3327. ⟨10.1093/jac/dkz344⟩, Journal of Antimicrobial Chemotherapy, 2019, Journal of Antimicrobial Chemotherapy, 74 (11), pp.3315-3327. ⟨10.1093/jac/dkz344⟩
- Publication Year :
- 2019
- Publisher :
- Oxford University Press (OUP), 2019.
-
Abstract
- Background First-line antifungal treatment for invasive mucormycosis (IM) consists of liposomal amphotericin B. Salvage treatment options are limited and often based on posaconazole oral suspension. With the approval of posaconazole new formulations, patients could benefit from improved pharmacokinetics, safety and tolerability. Objectives Our aim was to assess the effectiveness of posaconazole new formulations for IM treatment. Methods We performed a case-matched analysis with proven or probable IM patients from the FungiScope® Registry. First-line posaconazole new formulations (1st-POSnew) and first-line amphotericin B plus posaconazole new formulations (1st-AMB+POSnew) cases were matched with first-line amphotericin B-based (1st-AMB) treatment controls. Salvage posaconazole new formulations (SAL-POSnew) cases were matched with salvage posaconazole oral suspension (SAL-POSsusp) controls. Each case was matched with up to three controls (based on severity, haematological/oncological malignancy, surgery and/or renal dysfunction). Results Five patients receiving 1st-POSnew, 18 receiving 1st-AMB+POSnew and 22 receiving SAL-POSnew were identified. By day 42, a favourable response was reported for 80.0% (n = 4/5) of patients receiving 1st-POSnew, for 27.8% (n = 5/18) receiving 1st-AMB+POSnew and for 50.0% (n = 11/22) receiving SAL-POSnew. Day 42 all-cause mortality of patients receiving posaconazole new formulations was lower compared with controls [20.0% (n = 1/5) in 1st-POSnew versus 53.3% (n = 8/15) in 1st-AMB; 33.3% (n = 6/18) in 1st-AMB+POSnew versus 52.0% (n = 26/50) in 1st-AMB; and 0.0% (n = 0/22) in SAL-POSnew versus 4.4% (n = 2/45) in SAL-POSsusp]. Conclusions Posaconazole new formulations were effective in terms of treatment response and associated mortality of IM. While posaconazole new formulations may be an alternative for treatment of IM, the limited sample size of our study calls for a cautious interpretation of these observations.
- Subjects :
- Male
0301 basic medicine
Posaconazole
Antifungal Agents
[SDV]Life Sciences [q-bio]
Gastroenterology
0302 clinical medicine
[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases
Amphotericin B
Pharmacology (medical)
Prospective Studies
Registries
030212 general & internal medicine
Child
Prospective cohort study
[SDV.MP.MYC]Life Sciences [q-bio]/Microbiology and Parasitology/Mycology
ComputingMilieux_MISCELLANEOUS
Antiinfective agent
Standard treatment
Middle Aged
3. Good health
Infectious Diseases
Tolerability
Child, Preschool
Mucorales
Female
medicine.drug
Adult
Microbiology (medical)
medicine.medical_specialty
Adolescent
Drug Compounding
Matched-Pair Analysis
030106 microbiology
Young Adult
03 medical and health sciences
Pharmacokinetics
Internal medicine
parasitic diseases
medicine
Humans
Mucormycosis
[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology
[INFO]Computer Science [cs]
Aged
Pharmacology
business.industry
Infant, Newborn
Infant
Triazoles
medicine.disease
business
MESH: amphotericin b, antifungal agents, cancer, kidney failure, mucormycosis, surgical procedures, operative, suspensions, mortality, posaconazole
Invasive Fungal Infections
Subjects
Details
- ISSN :
- 14602091 and 03057453
- Volume :
- 74
- Database :
- OpenAIRE
- Journal :
- Journal of Antimicrobial Chemotherapy
- Accession number :
- edsair.doi.dedup.....f7aca142c2d95049170f5ec0a06400de